LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,944,444 ADSs. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $201.3 million.
Jefferies, Morgan Stanley, Cantor and William Blair acted as joint book-running managers for the offering.
A shelf registration statement relating to the securities in the offering described above was filed with the U.S. Securities and Exchange Commission (“SEC”) on May 18, 2026, and declared effective by the SEC on May 27, 2026. The offering was made by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement, as well as a related registration statement on Form S-3MEF. A final prospectus supplement and the accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at [email protected]; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.
For readers in the European Economic Area (“EEA”)
In any EEA member state (each, a “Relevant State”), this press release and any offering are only addressed to and directed at persons who are qualified investors (“Qualified Investors”) in that Relevant State within the meaning of the Prospectus Regulation. The term “Prospectus Regulation” means Regulation (EU) 2017/1129.
This press release must not be acted on or relied on in any EEA member state by persons who are not Qualified Investors. Any investment or investment activity to which this press release relates is available only to and will only be engaged with Qualified Investors in any EEA member state.
For readers in the United Kingdom
In the UK, this press release and any offering are only addressed to and directed at persons who are qualified investors (“UK Qualified Investors”) within the meaning of paragraph 15 of Part 2 of Schedule 1 of The Public Offers and Admissions to Trading Regulations 2024/105.
In the United Kingdom, this press release, in so far as it constitutes an invitation or inducement to enter into investment activity within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended (the “FSMA”), and any offering are only addressed to and directed at UK Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the “Order”, and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”).
This press release must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to and will only be engaged with relevant persons in the United Kingdom. This press release does not contain an offer or constitute any part of an offer to the public within the meaning of sections 85 and 102B of the FSMA or otherwise.
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate.
Silence Therapeutics PLC Sponsored ADR (SLN - Free Report) closed the last trading session at $13.58, gaining 30% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $32.6 indicates a 140.1% upside potential.
The mean estimate comprises five short-term price targets with a standard deviation of $26.01. While the lowest estimate of $4.00 indicates a 70.5% decline from the current price level, the most optimistic analyst expects the stock to surge 452.3% to reach $75.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
But, for SLN, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You May Not Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in SLNAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The Zacks Consensus Estimate for the current year has increased 1.6% over the past month, as two estimates have gone higher compared to no negative revision.
Moreover, SLN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much SLN could gain, the direction of price movement it implies does appear to be a good guide.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS. In addition, Silence.
Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company’s plan to advance a quarterly dosing regimen into Phase III.
PV is a rare myeloproliferative neoplasm in which elevated hematocrit levels can increase health risks. According to Chief R&D Officer Steven Romano, treatment is intended to keep hematocrit below 45%, often through therapeutic phlebotomy. SANRECO enrolled 48 patients who met World Health Organization criteria for PV and were considered phlebotomy-dependent, defined as having received at least three phlebotomies in the prior six months or five in the prior year.
Primary Endpoint Results The randomized, double-blind Phase II portion of SANRECO evaluated divesiran at 6 mg/kg administered every six weeks or every 12 weeks, compared with placebo. The primary endpoint was the proportion of patients maintaining hematocrit below 45% without requiring phlebotomy during weeks 18 through 36.
Romano said 88% of patients receiving divesiran across the combined active-treatment arms met the response criteria, compared with 18% of patients receiving placebo. The company reported a placebo-adjusted difference of nearly 70 percentage points and a p-value of less than 0.0001.
Both dosing schedules showed high response rates. The every-12-week arm had a response rate above 80%, while the every-six-week arm exceeded 90%, according to Romano. Although the study was powered to compare the combined active arms with placebo rather than each individual dosing arm with placebo, he said both schedules appeared to have “relatively similar” effects in the smaller individual groups.
A sensitivity analysis involving 40 patients who met the same phlebotomy-dependence criteria used in the company’s earlier Phase I study produced a divesiran response rate of nearly 90%, Romano said.
Phlebotomy and Secondary Measures The mean number of phlebotomies from week zero through week 36 was 0.2 among patients in the combined divesiran arms, compared with 2.1 among placebo patients. More than 90% of divesiran-treated patients did not require any phlebotomies during that period, versus 12.5% of placebo-treated patients.
Silence also said divesiran-treated groups showed improvements in secondary measures including hematocrit control, markers of iron metabolism such as ferritin, and patient-reported quality-of-life outcomes. The company plans to present more detailed data at future scientific meetings, including the American Society of Hematology meeting in New Orleans in December.
On symptom data, Romano said results from quality-of-life instruments, including measures focused on fatigue, were moving “in the right direction.” He said the company expects to use the Phase II findings to inform assumptions for a potentially more robustly powered symptom assessment in Phase III.
Safety Profile and Phase III Planning Romano said divesiran was generally well tolerated, with no new safety issues identified. Injection-site reactions were described as infrequent, grade 1 and self-limiting. The company reported two investigator-reported anemia adverse events, both grade 1 and not symptomatic; both occurred in the every-six-week arm.
The company also observed a modest increase in platelet counts, which Romano said was expected for a hepcidin-directed therapy that restricts iron availability to bone marrow. He said there was no change in white blood cell counts and that the safety observations were consistent with the company’s Phase I findings.
Silence plans to seek an end-of-Phase II meeting with the U.S. Food and Drug Administration by year-end and expects to begin a Phase III registration trial in the first half of 2027. Romano said the company intends to advance the less frequent every-12-week, or quarterly, dosing interval.
While final Phase III details have not been established, Romano said the company expects a parallel-group, one-to-one randomized design and anticipates discussions with the FDA regarding efficacy requirements and the size of the safety database. He said a trial could potentially involve roughly 200 to 250 patients and require an estimated 12 to 18 months for enrollment, though those details remain subject to regulatory discussions.
Chairman and Interim Principal Executive Officer Iain Ross said the company sees divesiran as a potential treatment for patients requiring phlebotomy regardless of whether they are also receiving stable cytoreductive therapy. He said Silence believes the data support a differentiated profile combining hematocrit control, reduced phlebotomy burden and infrequent dosing.
About Silence Therapeutics (NASDAQ:SLN) Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.
The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.
« PREVIOUS HEADLINEStevanato Group Q2 Earnings Call Highlights
NEXT HEADLINE »Talos Energy Q2 Earnings Call Highlights
Silence Therapeutics NASDAQ: SLN reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company’s plan to advance a quarterly dosing regimen into Phase III.
PV is a rare myeloproliferative neoplasm in which elevated hematocrit levels can increase health risks. According to Chief R&D Officer Steven Romano, treatment is intended to keep hematocrit below 45%, often through therapeutic phlebotomy. SANRECO enrolled 48 patients who met World Health Organization criteria for PV and were considered phlebotomy-dependent, defined as having received at least three phlebotomies in the prior six months or five in the prior year.
Get Silence Therapeutics alerts:
Primary Endpoint Results The randomized, double-blind Phase II portion of SANRECO evaluated divesiran at 6 mg/kg administered every six weeks or every 12 weeks, compared with placebo. The primary endpoint was the proportion of patients maintaining hematocrit below 45% without requiring phlebotomy during weeks 18 through 36.
Romano said 88% of patients receiving divesiran across the combined active-treatment arms met the response criteria, compared with 18% of patients receiving placebo. The company reported a placebo-adjusted difference of nearly 70 percentage points and a p-value of less than 0.0001.
Both dosing schedules showed high response rates. The every-12-week arm had a response rate above 80%, while the every-six-week arm exceeded 90%, according to Romano. Although the study was powered to compare the combined active arms with placebo rather than each individual dosing arm with placebo, he said both schedules appeared to have “relatively similar” effects in the smaller individual groups.
A sensitivity analysis involving 40 patients who met the same phlebotomy-dependence criteria used in the company’s earlier Phase I study produced a divesiran response rate of nearly 90%, Romano said.
Phlebotomy and Secondary Measures The mean number of phlebotomies from week zero through week 36 was 0.2 among patients in the combined divesiran arms, compared with 2.1 among placebo patients. More than 90% of divesiran-treated patients did not require any phlebotomies during that period, versus 12.5% of placebo-treated patients.
Silence also said divesiran-treated groups showed improvements in secondary measures including hematocrit control, markers of iron metabolism such as ferritin, and patient-reported quality-of-life outcomes. The company plans to present more detailed data at future scientific meetings, including the American Society of Hematology meeting in New Orleans in December.
On symptom data, Romano said results from quality-of-life instruments, including measures focused on fatigue, were moving “in the right direction.” He said the company expects to use the Phase II findings to inform assumptions for a potentially more robustly powered symptom assessment in Phase III.
Safety Profile and Phase III Planning Romano said divesiran was generally well tolerated, with no new safety issues identified. Injection-site reactions were described as infrequent, grade 1 and self-limiting. The company reported two investigator-reported anemia adverse events, both grade 1 and not symptomatic; both occurred in the every-six-week arm.
The company also observed a modest increase in platelet counts, which Romano said was expected for a hepcidin-directed therapy that restricts iron availability to bone marrow. He said there was no change in white blood cell counts and that the safety observations were consistent with the company’s Phase I findings.
Silence plans to seek an end-of-Phase II meeting with the U.S. Food and Drug Administration by year-end and expects to begin a Phase III registration trial in the first half of 2027. Romano said the company intends to advance the less frequent every-12-week, or quarterly, dosing interval.
While final Phase III details have not been established, Romano said the company expects a parallel-group, one-to-one randomized design and anticipates discussions with the FDA regarding efficacy requirements and the size of the safety database. He said a trial could potentially involve roughly 200 to 250 patients and require an estimated 12 to 18 months for enrollment, though those details remain subject to regulatory discussions.
Chairman and Interim Principal Executive Officer Iain Ross said the company sees divesiran as a potential treatment for patients requiring phlebotomy regardless of whether they are also receiving stable cytoreductive therapy. He said Silence believes the data support a differentiated profile combining hematocrit control, reduced phlebotomy burden and infrequent dosing.
About Silence Therapeutics (NASDAQ:SLN)Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence's technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.
The company's lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Silence Therapeutics Right Now?Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States. The proposed offering is a public offering registered under th.
Silence Therapeutics plc (NASDAQ:SLN) stock is trading higher on Monday after the company reported positive topline outcomes from its Phase 2 SANRECO study assessing divesiran for polycythemia vera. It is a rare, slow-growing blood cancer where the bone marrow makes too many red blood cells.
The extra production thickens the blood, slows down blood flow, and raises the risk of dangerous blood clots, heart attacks, and strokes.
The mid-stage trial successfully met both its primary and key secondary metrics, demonstrating strong efficacy alongside a favorable safety profile in phlebotomy-dependent trial participants.
Read Next
“The SANRECO Phase 2 trial delivered our best-case outcome, confirming the impressive results observed in Phase 1 with dosing every six weeks and demonstrating equally robust and durable effects with quarterly dosing,” said Curtis Rambaran, Chief Medical Officer at Silence.
SANRECO Study Meets Primary Efficacy EndpointsThe 36-week trial evaluated divesiran, a first-in-class short interfering RNA therapy, across 48 patients receiving a 6 mg/kg subcutaneous dose every six or twelve weeks.
Overall, 88% of divesiran-treated patients achieved the primary endpoint—defined as the absence of phlebotomies while maintaining hematocrit levels below 45% between weeks 18 and 36—compared to just 19% of placebo recipients.
Dosing schedules administered every six weeks and every twelve weeks demonstrated response rates of 93.8% and 81.3%, respectively, yielding a placebo-adjusted response rate of 69%.
Secondary Outcomes And Tolerability ProfileThe clinical trial also achieved key secondary endpoints during the 36-week timeframe.
Divesiran significantly decreased phlebotomy (vein puncturing) requirements, with treated subjects averaging 0.2 phlebotomies compared to 2.1 procedures in the placebo arm.
Participants receiving divesiran also showed enhancements in hematocrit management, iron ferritin markers, and symptom reductions recorded through the MPN-SAF Total Symptom Score.
Divesiran was well tolerated throughout the study, showing safety results consistent with earlier clinical evaluations.
No new safety concerns emerged, and reported injection site reactions were infrequent and self-limiting.
Two investigator-reported grade 1 anemia adverse events occurred. Based on these results, a Phase 3 trial comparing twelve-week divesiran administration to placebo is expected to launch in the first half of 2027.
The company reported a cash balance of $72.1 million as of June 30, 2026.
SLN Price Action: Silence Therapeutics shares were up 36.82% at $16.35 at the time of publication on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro data.
Read Next
Image via Shutterstock/ Yomal2233
Market News and Data brought to you by Benzinga APIs
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders Presented follow-up data from the Phase 1 SANRECO trial at the European Hematology Association (EHA) 2026 Annual Congress in J.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV). The 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran (6 mg/kg) administered subcutaneously (s.c.) ev.
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT. Investor Webcast & Conference Call Information Conference call link: https://register-conf.media-server.com/register/BI4a60039edc0.
Key Takeaways SLN completed SANRECO enrollment ahead of schedule, accelerating the top-line data to August 2026.SLN is seeking a strategic partner to advance phase III-ready zerlasiran after positive FDA and EMA feedback.Silence Therapeutics regained global rights to SLN312 after AstraZeneca ended the program's development. Shares of Silence Therapeutics (SLN - Free Report) have surged 107% over the past six months, driven by investor optimism around the company's advancing RNA interference (siRNA) pipeline, upcoming clinical data readouts and the long-term growth potential of its lead candidate, divesiran.
Divesiran: SLN’s Major Growth DriverInvestor sentiment has been fueled by the rapid clinical progress of divesiran, Silence Therapeutics’ first-in-class siRNA therapy targeting TMPRSS6 for the treatment of patients with polycythemia vera (PV), a rare myeloproliferative blood cancer characterized by excessive production of red blood cells and elevated hematocrit levels.
The ongoing phase II SANRECO study is evaluating divesiran at a 6 mg dose with every-six-week (Q6W) and every-12-week (Q12W) dosing schedules in patients with PV. The study completed patient enrollment ahead of schedule. As a result, the company accelerated the anticipated top-line data readout from the second half of 2026 to the third quarter of 2026 (August 2026). Positive study data could serve as a significant catalyst for the stock. Earlier phase I data demonstrated meaningful reductions in phlebotomy requirements, improvements in disease-related symptoms and quality of life and a favorable safety profile.
Year to date, shares of Silence Therapeutics have jumped 71.9% against the industry’s 1.5% drop.
Image Source: Zacks Investment Research
SLN’s Other Pipeline Assets on the MoveBeyond divesiran, Silence Therapeutics continues to strengthen its long-term growth outlook through a diversified RNAi pipeline. Zerlasiran (SLN360) is SLNs’ phase III-ready siRNA candidate for cardiovascular disease associated with elevated lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart attack and stroke. In phase I and phase II studies, zerlasiran demonstrated substantial and durable reductions in Lp(a) with infrequent dosing and a favorable safety profile. Following positive regulatory feedback from the FDA and EMA, and the completion of key phase III readiness activities, the company is seeking a strategic partner to advance late-stage development and commercialization of the program.
SLN312 Faces Development Setback Following AstraZeneca ExitAnother promising asset, SLN312, is an siRNA therapy targeting ANGPTL3 for the treatment of dyslipidemia. However, the candidate faced a setback in March, after its former partner, AstraZeneca (AZN - Free Report) , decided to discontinue further development of the program following a phase I study. Although the study demonstrated durable, dose-dependent reductions in ANGPTL3, triglycerides and atherogenic lipoproteins, along with a favorable safety profile and the potential for infrequent dosing, AZN chose not to advance the candidate into later-stage development. As a result, Silence Therapeutics will regain global rights to SLN312 and must now determine the program's future, either by funding its development internally or securing a new strategic partner.
SLN’s Zacks Rank & Stocks to ConsiderSilence Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.48. Over the same period, EPS estimates for 2027 have increased from $10.23 to $10.79. NBIX shares have gained 21.3% year to date.
Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen to $4.92 from $4.81. LQDA shares have surged 125.4% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Silence Therapeutics (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
I initiate Silence Therapeutics at a speculative Buy, driven by near-term divesiran/SLN124 catalysts in polycythemia vera (PV). SLN's mRNAi GOLD GalNAc-siRNA platform enables infrequent dosing and strong target knockdown, potentially differentiating divesiran from weekly competitors like Rusfertide. Phase 1 SANRECO data show promising phlebotomy reduction and symptom improvement, but safety and efficacy require confirmation in the pivotal Phase 2 readout (August 2026).
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Silence Therapeutics Plc (NASDAQ:SLN) stock rose Wednesday after Cantor Fitzgerald initiated coverage with an Overweight rating and a positive outlook for its lead drug candidate.
Cantor Fitzgerald initiated coverage of Silence Therapeutics with an Overweight rating, arguing that the biotech’s lead candidate divesiran could emerge as a major challenger in the polycythemia vera market, with upcoming Phase 2 data expected in August serving as a potentially transformative catalyst and supporting a valuation upside of more than 160%.
Ongoing Phase 2 Study Could Be Major CatalystPV is a rare, slow-growing blood cancer that causes the bone marrow to produce too many red blood cells.
SANRECO Phase 2 study evaluating divesiran 6 mg (Q6W and Q12W dosing intervals) in 48 phlebotomy-dependent PV patients is ongoing, with topline results on track for August 2026.
Cantor analyst Prakhar Agrawal wrote, “We are positive on the upcoming P2 PV trial and expect divesiran to show rusfertide-like efficacy while offering a meaningful dosing convenience advantage (every 6-weeks or every 12 weeks), compared with rusfertide’s weekly dosing regimen.”
Dosing Convenience Seen As Competitive AdvantageThe study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received FDA Orphan Drug and Fast Track designations.
Cantor noted that KOL checks suggest that, assuming comparable efficacy and safety to rusfertide, even an every 6-week dosing schedule could support meaningful uptake of divesiran in PV.
At a market cap of just $300 million, analyst Agrawal sees Silence Therapeutics as materially undervalued and initiated with an Overweight rating.
The analyst sees a high 75% probabilty of success for the Phase 2 PV trial, supported by divesiran’s strong Phase 1 data in PV with 100% response rate in well-controlled PV patients, and the valuation benchmark set by rusfertide in PV following its positive Phase 2 results.
Cantor says the valuation range implies over 160% upside from current levels. Risk/reward is very attractive for Phase 2.
Silence Therapeutics Price ActionSLN Price Action: Silence Therapeutics shares were up 22.90% at $8.93 at the time of publication on Wednesday. The stock is trading at a new 52-week high, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life
Follow-up data show substantial reductions in phlebotomy use persisting after final dose
Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in August 2026
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2026 Annual Congress.
Divesiran data presented at EHA show improvements in PV-related symptoms and quality-of-life, complementing the substantial reductions in phlebotomy use as previously reported. Additional analyses also showed substantial reductions in phlebotomy use persisted well beyond the final dose.
“Data presented at EHA continue to reinforce divesiran’s potential to transform the treatment paradigm for patients with polycythemia vera,” said Curtis Rambaran, MD, Chief Medical Officer at Silence Therapeutics. “In Phase 1, we observed sustained hematocrit control, symptom improvement, and robust and durable reductions in phlebotomy burden, which persisted after the final dose. These findings further support the potential for less frequent dosing, including the Q12W regimen being evaluated in our ongoing Phase 2 SANRECO study, and we look forward to reporting topline results in August 2026.”
Key EHA 2026 Data Highlights
In the six months prior to treatment, the 21 enrolled patients required a total of 80 phlebotomies. During the active treatment period, only 5 phlebotomies were required, all occurring in patients classified as “uncontrolled” at baseline with HCT levels greater than 45%. During the 16-week follow-up period after the final dose, only 4 phlebotomies were reported, supporting the prolonged duration of divesiran’s effect. Among 14 patients with further follow-up data, the median time to first phlebotomy was 287 days. The majority of patients experienced improvements in MPN-10 total symptom scores from baseline through Week 34, indicating potential improvements in disease-related symptoms and overall quality of life. Divesiran was well tolerated, with no dose-limiting toxicities observed. The most common treatment-emergent adverse events (TEAEs) were mild and transient injection-site reactions. No treatment-related serious adverse events or TEAEs leading to discontinuation were reported. The 2026 EHA poster presentation is linked here.
The ongoing Phase 2 SANRECO study (NCT05499013) is evaluating divesiran using Q6W and Q12W dosing regimens in patients with PV. Topline data are expected in August 2026.
SANRECO Phase 1 Study Design
The Phase 1 portion of SANRECO was a 34-week, open-label study evaluating divesiran (3 mg/kg, 6 mg/kg and 9 mg/kg) administered subcutaneously (s.c.) Q6W for four doses, with a 16-week follow-up period following the date of the last administered dose in 21 PV patients. Key inclusion criteria included a PV diagnosis and a history of requiring at least three phlebotomies in the last six months or five in the last year prior to screening. Patients were allowed to be on stable doses of cytoreductive agents. Given the exploratory nature of this Phase 1 study, both well-controlled patients - defined as those with HCT levels ≤ 45% – as well as those with HCT levels > 45% at baseline on current standard-of-care treatment were enrolled.
SANRECO Phase 2 Study Design
The Phase 2 portion of SANRECO is an ongoing, three-part, global, randomized, placebo-controlled, double-blind study evaluating divesiran in 48 phlebotomy-dependent PV patients. The trial is evaluating the safety and efficacy of divesiran 6 mg administered s.c. Q6W or Q12W in patients with uncontrolled HCT who are phlebotomy-dependent despite standard-of-care treatment which could include hydroxyurea, interferon and/or ruxolitinib. The primary endpoint of the study is the proportion of patients achieving a response during weeks 18-36, which is defined as the absence of “phlebotomy eligibility.” To meet phlebotomy eligibility, patients in the study are required to have HCT ≥ 45%. Following the placebo-controlled portion of the trial, patients enter the 3-year, double-blind and open label extension periods.
About PV
PV is a rare, myeloproliferative neoplasm – a type of blood cancer - characterized by the excessive production of red blood cells, often resulting in elevated hematocrit levels. Elevated hematocrit above 45-percent is associated with a four-times higher rate of death from cardiovascular and thrombotic events. PV is associated with a range of burdensome symptoms including fatigue, cognitive disturbance and pruritus and additionally, longer term can transform to myelofibrosis and Acute Myeloid Leukemia. The aim of treatment is to maintain hematocrit less than 45%, a level that is associated with a reduced incidence of thrombosis and CV-associated death. The current standard of care includes repeated phlebotomies to reduce hematocrit and/or cytoreductive agents to reduce red blood cell production. There are currently no approved therapies that specifically target red blood cells and hematocrit.
About Divesiran
Divesiran is Silence’s wholly owned siRNA product candidate developed from its proprietary mRNAi GOLD™ platform that “silences” TMPRSS6 expressed almost exclusively in the liver. TMPRSS6 is a negative regulator of hepcidin, the body's master regulator of iron metabolism including its absorption, distribution, and storage. By silencing TMPRSS6 in PV patients, divesiran aims to increase hepcidin production and release by liver hepatocytes, leading to the restriction of iron to the bone marrow and, thus, reducing the excessive production of red blood cells, a process dependent on availability of iron. Divesiran is currently in Phase 2 development for PV and has FDA Fast Track and Orphan Drug designations for PV.
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: continued clinical development of divesiran including the proposed SANRECO Phase 2 clinical activities and timelines; the potential therapeutic benefits of the Company’s product candidates; and the anticipated timing of topline and future results from the SANRECO Phase 2 trial. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2026 Annual Congress.
Divesiran data presented at EHA show improvements in PV-related symptoms and quality-of-life, complementing the substantial reductions in phlebotomy use as previously reported. Additional analyses also showed substantial reductions in phlebotomy use persisted well beyond the final dose.
“Data presented at EHA continue to reinforce divesiran’s potential to transform the treatment paradigm for patients with polycythemia vera,” said Curtis Rambaran, MD, Chief Medical Officer at Silence Therapeutics. “In Phase 1, we observed sustained hematocrit control, symptom improvement, and robust and durable reductions in phlebotomy burden, which persisted after the final dose. These findings further support the potential for less frequent dosing, including the Q12W regimen being evaluated in our ongoing Phase 2 SANRECO study, and we look forward to reporting topline results in August 2026.”
Key EHA 2026 Data Highlights
In the six months prior to treatment, the 21 enrolled patients required a total of 80 phlebotomies. During the active treatment period, only 5 phlebotomies were required, all occurring in patients classified as “uncontrolled” at baseline with HCT levels greater than 45%. During the 16-week follow-up period after the final dose, only 4 phlebotomies were reported, supporting the prolonged duration of divesiran’s effect. Among 14 patients with further follow-up data, the median time to first phlebotomy was 287 days. The majority of patients experienced improvements in MPN-10 total symptom scores from baseline through Week 34, indicating potential improvements in disease-related symptoms and overall quality of life. Divesiran was well tolerated, with no dose-limiting toxicities observed. The most common treatment-emergent adverse events (TEAEs) were mild and transient injection-site reactions. No treatment-related serious adverse events or TEAEs leading to discontinuation were reported. The 2026 EHA poster presentation is linked here.
The ongoing Phase 2 SANRECO study (NCT05499013) is evaluating divesiran using Q6W and Q12W dosing regimens in patients with PV. Topline data are expected in August 2026.
SANRECO Phase 1 Study Design
The Phase 1 portion of SANRECO was a 34-week, open-label study evaluating divesiran (3 mg/kg, 6 mg/kg and 9 mg/kg) administered subcutaneously (s.c.) Q6W for four doses, with a 16-week follow-up period following the date of the last administered dose in 21 PV patients. Key inclusion criteria included a PV diagnosis and a history of requiring at least three phlebotomies in the last six months or five in the last year prior to screening. Patients were allowed to be on stable doses of cytoreductive agents. Given the exploratory nature of this Phase 1 study, both well-controlled patients - defined as those with HCT levels ≤ 45% – as well as those with HCT levels > 45% at baseline on current standard-of-care treatment were enrolled.
SANRECO Phase 2 Study Design
The Phase 2 portion of SANRECO is an ongoing, three-part, global, randomized, placebo-controlled, double-blind study evaluating divesiran in 48 phlebotomy-dependent PV patients. The trial is evaluating the safety and efficacy of divesiran 6 mg administered s.c. Q6W or Q12W in patients with uncontrolled HCT who are phlebotomy-dependent despite standard-of-care treatment which could include hydroxyurea, interferon and/or ruxolitinib. The primary endpoint of the study is the proportion of patients achieving a response during weeks 18-36, which is defined as the absence of “phlebotomy eligibility.” To meet phlebotomy eligibility, patients in the study are required to have HCT ≥ 45%. Following the placebo-controlled portion of the trial, patients enter the 3-year, double-blind and open label extension periods.
About PV
PV is a rare, myeloproliferative neoplasm – a type of blood cancer - characterized by the excessive production of red blood cells, often resulting in elevated hematocrit levels. Elevated hematocrit above 45-percent is associated with a four-times higher rate of death from cardiovascular and thrombotic events. PV is associated with a range of burdensome symptoms including fatigue, cognitive disturbance and pruritus and additionally, longer term can transform to myelofibrosis and Acute Myeloid Leukemia. The aim of treatment is to maintain hematocrit less than 45%, a level that is associated with a reduced incidence of thrombosis and CV-associated death. The current standard of care includes repeated phlebotomies to reduce hematocrit and/or cytoreductive agents to reduce red blood cell production. There are currently no approved therapies that specifically target red blood cells and hematocrit.
About Divesiran
Divesiran is Silence’s wholly owned siRNA product candidate developed from its proprietary mRNAi GOLD™ platform that “silences” TMPRSS6 expressed almost exclusively in the liver. TMPRSS6 is a negative regulator of hepcidin, the body's master regulator of iron metabolism including its absorption, distribution, and storage. By silencing TMPRSS6 in PV patients, divesiran aims to increase hepcidin production and release by liver hepatocytes, leading to the restriction of iron to the bone marrow and, thus, reducing the excessive production of red blood cells, a process dependent on availability of iron. Divesiran is currently in Phase 2 development for PV and has FDA Fast Track and Orphan Drug designations for PV.
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: continued clinical development of divesiran including the proposed SANRECO Phase 2 clinical activities and timelines; the potential therapeutic benefits of the Company’s product candidates; and the anticipated timing of topline and future results from the SANRECO Phase 2 trial. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260611005104/en/
SLN Stock Catalyst: SANRECO Phase 1 Follow-Up DataRecent analyses from the Phase 1 SANRECO study show potential improvements in symptoms and quality of life for patients with polycythemia vera (PV).
Additional analyses also showed reductions in phlebotomy use persisted well beyond the final dose.
The ongoing Phase 2 SANRECO study is on track to deliver topline results in August 2026, further supporting the stock’s upward movement.
William Blair Highlights Divesiran’s Competitive PositionWilliam Blair said Thursday that additional analyses from the Phase 1 SANRECO trial reinforce positive momentum for Silence Therapeutics and divesiran in polycythemia vera (PV), with topline Phase 2 data expected in the third quarter.
Analyst Myles Minter believes divesiran offers comparable efficacy and remains best-in-class among TMPRSS6 silencers. He highlighted its favorable dosing schedule (every 6–12 weeks versus weekly rusfertide injections) and safety profile.
Cardiovascular Pipeline Offers Additional UpsideThe analyst also pointed to Silence's cardiovascular disease pipeline, which targets well-validated pathways, as providing multiple value-creation opportunities for the company's mRNAi GOLD platform.
William Blair reiterated its Outperform rating.
SLN Stock Price Activity: Silence Therapeutics shares were up 2.84% at $6.87 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock/ Yomal2233
Market News and Data brought to you by Benzinga APIs
Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) and Silence Therapeutics (NASDAQ: SLN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership. Insider and Institutional Ownership 87.1% of Avalo
Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $34.50.
Several research analysts have issued reports on SLN shares. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 13th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Jefferies Financial Group raised Silence Therapeutics to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Thursday, January 22nd.
Read Our Latest Stock Report on Silence Therapeutics
Silence Therapeutics Stock Performance Shares of NASDAQ SLN opened at $5.94 on Friday. The business has a fifty day moving average of $5.43 and a two-hundred day moving average of $5.88. Silence Therapeutics has a 52-week low of $1.97 and a 52-week high of $7.91. The stock has a market cap of $280.55 million, a PE ratio of -3.18 and a beta of 1.33.
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.07. Silence Therapeutics had a negative net margin of 15,851.88% and a negative return on equity of 101.71%. The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $2.19 million. Analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current year.
Institutional Inflows and Outflows A number of institutional investors have recently bought and sold shares of SLN. Seven Fleet Capital Management LP acquired a new position in shares of Silence Therapeutics in the 4th quarter valued at $897,000. XTX Topco Ltd acquired a new position in Silence Therapeutics in the 4th quarter worth $71,000. Quadrature Capital Ltd bought a new position in Silence Therapeutics during the 4th quarter worth about $331,000. Opaleye Management Inc. acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at about $480,000. Finally, Millennium Management LLC lifted its holdings in shares of Silence Therapeutics by 121.0% in the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock valued at $4,010,000 after purchasing an additional 361,080 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.
About Silence Therapeutics (Get Free Report)
Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.
The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.
Read More Five stocks we like better than Silence Therapeutics
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECoupang, Inc. (NYSE:CPNG) Given Consensus Rating of “Hold” by Brokerages
NEXT HEADLINE »Crane NXT, Co. (NYSE:CXT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Silence Therapeutics PLC Sponsored ADR (SLN - Free Report) shares rallied 19% in the last trading session to close at $7.28. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.4% loss over the past four weeks.
Silence Therapeutics’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments. SLN continues to advance its siRNA pipeline with multiple near-term catalysts. Its lead candidate, divesiran for polycythemia vera (PV), has seen accelerated timelines, with phase II SANRECO topline data expected in the third quarter 2026 due to faster enrollment. The company’s zerlasiran, targeting elevated lipoprotein(a), is Phase III–ready and could attract a development partner. In earlier stages, SLN365 for cholesterol and SLN098 for obesity are showing encouraging preclinical progress, underscoring the potential of its mRNAi GOLD platform, with multiple updates anticipated throughout 2026.
This company is expected to post quarterly loss of $0.33 per share in its upcoming report, which represents a year-over-year change of +45%. Revenues are expected to be $6 million, up 4185.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Silence Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SLN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Silence Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Guardian Pharmacy Services (GRDN - Free Report) , closed the last trading session 1.9% lower at $37.09. Over the past month, GRDN has returned 10.9%.
For Guardian Pharmacy, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.24. This represents a change of +14.3% from what the company reported a year ago. Guardian Pharmacy currently has a Zacks Rank of #1 (Strong Buy).
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2026, and provided an update on recent business achievements. “The Silence team continues to advance research supporting the broad potential of our mRNAi GOLD™ platform, and we remain well positioned as we approach a significant company mile.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archiv.
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET. A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be avail.
